"Ascletis receives FDA clearance for Phase I trial of obesity treatment" was originally created and published by Clinical ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

GLP-1 receptor agonists are a class of medications that mimic the action of a natural hormone called glucagon-like peptide-1.

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated ...

Horizon has paid an upfront fee and committed to development, regulatory and sales milestones. (iStock / Getty Images Plus) Horizon Therapeutics has teamed up with Xeris Biopharma to create an ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Sanofi's subcutaneous formulation of multiple myeloma drug Sarclisa has been approved in the UK, which will be the first market for the on-body injector (OBI) version of the drug.